Skip to content
Screener

Ligand Pharmaceuticals LGND Financial Royalty Assets, Net

Financial Royalty Assets, Net at other companies

Royalty Pharma logo
Royalty PharmaRPRX
$814.85M+12.2%
Royalty Pharma logo
Royalty PharmaRPRX
$814.85M+12.2%
Royalty Pharma logo
Royalty PharmaRPRX
$814.85M+12.2%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$426.79M-11.7%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$43.81M+22.6%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$382.98M-14.5%

Segments

By product

See full
Agenus Inc.$40.41M

Other financials

Income statement

See full
Revenue$63.7M+33.7%
Operating income$8.6M+1.7%
Net income$48.5M+901%
EPS (diluted)$2.22+825%

Balance sheet

See full
Cash & equivalents$1.0B+1,388%
Total debt$1.1B+19,605%
Total equity$967.5M+16.9%
Total assets$2.2B+130%

Cash flow

See full
Operating cash flow$24.0M+52.0%
CapEx$26.0K-87.9%
Free cash flow$24.0M+53.9%

Valuation

See full
Market cap$6.02B+119%
Enterprise value$6.14B+129%
P/E30.5×
P/S20.7×+6.1×

Profitability

See full
Gross margin91.9%
Operating margin32.6%+24.0pp
Net margin67.9%+49.4pp
FCF margin45.2%+16.7pp

Returns & leverage

See full
Return on equity22%+16.9pp
Debt / equity1.2×+1.2×
Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsNet.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000886163-26-000044
Line itemJune 30, 2026 / Gross carrying value(1)June 30, 2026 / AllowanceJune 30, 2026 / Net carrying value (1)December 31, 2025 / Gross carrying value(1)December 31, 2025 / AllowanceDecember 31, 2025 / Net carrying value(1)
Tolerance Therapeutics (Tzield®)25,470(99)25,37125,257(98)25,159
Ohtuvayre inventors19,957(179)19,77816,921(151)16,770
Elutia (CorMatrix)6,062(837)5,2256,607(1,107)5,500
AT2204,442(109)4,3335,132(132)5,000
Primrose mRNA3,281(98)3,1833,281(98)3,183
Zerion2,640(79)2,561
Others5,729(212)5,5175,769(214)5,555
Total financial royalty assets, net$209,699$(2,489)$207,210$222,375$(2,706)$219,669

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's financial royalty assets, net?
Ligand Pharmaceuticals (LGND) reported financial royalty assets, net of $207.21M in Q2 2026.
How has Ligand Pharmaceuticals's financial royalty assets, net changed year-over-year?
Ligand Pharmaceuticals's financial royalty assets, net increased by 1.7% year-over-year, from $203.83M to $207.21M.
What is the long-term trend for Ligand Pharmaceuticals's financial royalty assets, net?
Over 2 years (2023 to 2025), Ligand Pharmaceuticals's financial royalty assets, net has grown at a 87.8% compound annual growth rate (CAGR), from $62.29M to $219.67M.
What does financial royalty assets, net mean?
Financial Royalty Assets, Net as reported by Ligand Pharmaceuticals Inc..

Ask your AI about Ligand Pharmaceuticals's financial royalty assets, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude